IRIS Accounts Production v24.2.0.383 04946997 Board of Directors 1.1.23 31.12.23 31.12.23 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh049469972022-12-31049469972023-12-31049469972023-01-012023-12-31049469972021-12-31049469972022-01-012022-12-31049469972022-12-3104946997ns15:EnglandWales2023-01-012023-12-3104946997ns14:PoundSterling2023-01-012023-12-3104946997ns10:Director12023-01-012023-12-3104946997ns10:PrivateLimitedCompanyLtd2023-01-012023-12-3104946997ns10:SmallEntities2023-01-012023-12-3104946997ns10:AuditExemptWithAccountantsReport2023-01-012023-12-3104946997ns10:SmallCompaniesRegimeForDirectorsReport2023-01-012023-12-3104946997ns10:SmallCompaniesRegimeForAccounts2023-01-012023-12-3104946997ns10:FullAccounts2023-01-012023-12-3104946997ns10:Director22023-01-012023-12-3104946997ns10:Director32023-01-012023-12-3104946997ns10:Director42023-01-012023-12-3104946997ns10:CompanySecretary12023-01-012023-12-3104946997ns10:RegisteredOffice2023-01-012023-12-3104946997ns5:CurrentFinancialInstruments2023-12-3104946997ns5:CurrentFinancialInstruments2022-12-3104946997ns5:ShareCapital2023-12-3104946997ns5:ShareCapital2022-12-3104946997ns5:SharePremium2023-12-3104946997ns5:SharePremium2022-12-3104946997ns5:RetainedEarningsAccumulatedLosses2023-12-3104946997ns5:RetainedEarningsAccumulatedLosses2022-12-3104946997ns5:PlantMachinery2022-12-3104946997ns5:FurnitureFittings2022-12-3104946997ns5:PlantMachinery2023-01-012023-12-3104946997ns5:FurnitureFittings2023-01-012023-12-3104946997ns5:PlantMachinery2023-12-3104946997ns5:FurnitureFittings2023-12-3104946997ns5:PlantMachinery2022-12-3104946997ns5:FurnitureFittings2022-12-3104946997ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-12-3104946997ns5:CurrentFinancialInstrumentsns5:WithinOneYear2022-12-31
REGISTERED NUMBER: 04946997 (England and Wales)















Unaudited Financial Statements

for the Year Ended 31 December 2023

for

XYTAL HEALTH MANAGEMENT LIMITED

XYTAL HEALTH MANAGEMENT LIMITED (REGISTERED NUMBER: 04946997)

Contents of the Financial Statements
for the year ended 31 December 2023










Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4

Accountants' Report 9

XYTAL HEALTH MANAGEMENT LIMITED

Company Information
for the year ended 31 December 2023







Directors: Mr K J Ball
Mrs S P More
Dr R E A More
Mrs V Watts





Secretary: Dr R E A More





Registered office: 3rd Floor,
207 Regent Street,
London
W1B 3HH





Registered number: 04946997 (England and Wales)





Accountants: Cooper Parry Advisory Limited
Aissela
46 High Street
Esher
Surrey
KT10 9QY

XYTAL HEALTH MANAGEMENT LIMITED (REGISTERED NUMBER: 04946997)

Balance Sheet
31 December 2023

2023 2022
Notes £ £ £ £
Fixed assets
Tangible assets 4 89,718 97,145

Current assets
Debtors 5 610,919 366,552
Cash at bank 283,308 592,174
894,227 958,726
Creditors
Amounts falling due within one year 6 455,700 557,995
Net current assets 438,527 400,731
Total assets less current liabilities 528,245 497,876

Provisions for liabilities 14,725 6,580
Net assets 513,520 491,296

Capital and reserves
Called up share capital 61 61
Share premium 1,625 1,625
Retained earnings 511,834 489,610
Shareholders' funds 513,520 491,296

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2023 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

XYTAL HEALTH MANAGEMENT LIMITED (REGISTERED NUMBER: 04946997)

Balance Sheet - continued
31 December 2023


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Profit and Loss Account has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 10 September 2024 and were signed on its behalf by:





Dr R E A More - Director


XYTAL HEALTH MANAGEMENT LIMITED (REGISTERED NUMBER: 04946997)

Notes to the Financial Statements
for the year ended 31 December 2023


1. Statutory information

Xytal Health Management Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. Accounting policies

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Key source of estimation, uncertainty and judgement
The preparation of financial statements in conformity with generally accepted accounting practice requires management to make estimates and judgement that affect the reported amounts of assets and liabilities as well as the disclosure of contingent assets and liabilities at the balance sheet date and the reported amounts of revenues and expenses during the reporting period.

There is estimation uncertainty in calculating depreciation. A full line by line review of fixed assets is carried out by management regularly. Whilst every attempt is made to ensure that the depreciation policy is as accurate as possible, there remains a risk that the policy does not match the useful life of the assets.

Turnover
Revenue from contracts for the provision of services is recognised by reference to the completed practice visits and other associated work on a monthly basis. Work is prearranged on a tracking tool which is updated weekly for all visits that take place. At month end the fully completed tracking tool is used to populate monthly invoices for the services rendered.

XYTAL HEALTH MANAGEMENT LIMITED (REGISTERED NUMBER: 04946997)

Notes to the Financial Statements - continued
for the year ended 31 December 2023


2. Accounting policies - continued

Tangible fixed assets
Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:


Plant and equipment 10/25 Years Straight Line

Fixtures and fittings 25% Reducing Balance


The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

Impairment of fixed assets
At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash­ generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

Cash at bank and in hand
Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

XYTAL HEALTH MANAGEMENT LIMITED (REGISTERED NUMBER: 04946997)

Notes to the Financial Statements - continued
for the year ended 31 December 2023


2. Accounting policies - continued

Financial instruments
Financial assets and financial liabilities are recognised in the balance sheet when the company becomes a party to the contractual provisions of the instrument.

Trade and other debtors and creditors are classified as basic financial instruments and measured at initial recognition at transaction price. Debtors and creditors are subsequently measured at amortised cost using the effective interest rate method. A provision is established when there is objective evidence that the company will not be able to collect all amounts due.

Cash and cash equivalents are classified as basic financial instruments and comprise cash in hand and at bank and bank overdrafts.

Financial liabilities and equity instruments issued by the company are classified in accordance with the substance of the contractual arrangements entered into and the definitions of a financial liability and an equity instrument. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities. Equity instruments issued by the company are recorded at the proceeds received, net of direct issue costs.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Profit and Loss Account, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Research and development
Research expenditure is written off against profit in the year in which it is incurred. Identifiable development expenditure is capitalised to the extent that the technical commercial and financial feasibility can be demonstrated.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

XYTAL HEALTH MANAGEMENT LIMITED (REGISTERED NUMBER: 04946997)

Notes to the Financial Statements - continued
for the year ended 31 December 2023


2. Accounting policies - continued

Employee benefits
The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

3. Employees and directors

The average number of employees during the year was 9 (2022 - 9 ) .

4. Tangible fixed assets
Fixtures
Plant and and
machinery fittings Totals
£ £ £
Cost
At 1 January 2023 101,894 18,225 120,119
Additions 857 386 1,243
At 31 December 2023 102,751 18,611 121,362
Depreciation
At 1 January 2023 13,298 9,676 22,974
Charge for year 6,436 2,234 8,670
At 31 December 2023 19,734 11,910 31,644
Net book value
At 31 December 2023 83,017 6,701 89,718
At 31 December 2022 88,596 8,549 97,145

5. Debtors: amounts falling due within one year
2023 2022
£ £
Trade debtors 584,309 321,726
Other debtors 26,610 44,826
610,919 366,552

XYTAL HEALTH MANAGEMENT LIMITED (REGISTERED NUMBER: 04946997)

Notes to the Financial Statements - continued
for the year ended 31 December 2023


6. Creditors: amounts falling due within one year
2023 2022
£ £
Trade creditors 134,717 289,396
Taxation and social security 227,758 180,545
Other creditors 93,225 88,054
455,700 557,995

7. Directors' advances, credits and guarantees

At the beginning of the year, the company owed the director £5,883. Further repayment has been made and as of 31 December 2023 the company owed the director £1,441.

This loan is interest free and repayable on demand.

Accountants' Report to the Board of Directors
on the Unaudited Financial Statements of
Xytal Health Management Limited


The following reproduces the text of the report prepared for the directors in respect of the company's annual unaudited financial statements. In accordance with the Companies Act 2006, the company is only required to file a Balance Sheet. Readers are cautioned that the Income Statement and certain other primary statements and the Report of the Directors are not required to be filed with the Registrar of Companies.

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Xytal Health Management Limited for the year ended 31 December 2023 which comprise the Profit and Loss Account, Balance Sheet and the related notes from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed within the ICAEW's regulations and guidance at http://www.icaew.com/en/membership/regulations-standards-and-guidance.

This report is made solely to the Board of Directors of Xytal Health Management Limited, as a body, in accordance with our terms of engagement. Our work has been undertaken solely to prepare for your approval the financial statements of Xytal Health Management Limited and state those matters that we have agreed to state to the Board of Directors of Xytal Health Management Limited, as a body, in this report in accordance with ICAEW Technical Release 07/16AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Xytal Health Management Limited and its Board of Directors, as a body, for our work or for this report.

It is your duty to ensure that Xytal Health Management Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and profit of Xytal Health Management Limited. You consider that Xytal Health Management Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of Xytal Health Management Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.






Cooper Parry Advisory Limited
Aissela
46 High Street
Esher
Surrey
KT10 9QY


20 September 2024